The beat and guidance raise signal improving commercial traction from new products. Watch for H2 2026 revenue growth to turn positive as headwinds annualize; the stock may continue to re-rate if sequential improvement persists.
Price Chart
Executive Summary
Treace Medical Concepts reported Q2 2026 revenue of $45.4M (down 4% YoY but beating $43.9M consensus) and EPS of -$0.24 (beating -$0.30 consensus by 20%). The company raised full-year revenue guidance to $204M-$212M and improved Adjusted EBITDA loss guidance to $3M-$5M, while reducing year-to-date cash usage by 57%. New product adoption is accelerating, with 40% of Lapiplasty surgeons now using at least one of the three new bunion systems.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $45.4M vs $47.4M YoY (-4%), beating consensus of $43.9M
- Q2 2026 GAAP EPS -$0.24 vs -$0.28 YoY, beating consensus of -$0.30
- Full-year 2026 revenue guidance raised to $204M-$212M (from $202M-$212M)
- Adjusted EBITDA loss guidance improved to $3.0M-$5.0M (from $4.0M-$6.0M)
- Year-to-date cash usage reduced 57% vs prior year; cash + marketable securities $45.6M
- Gross margin 78.5% vs 79.7% YoY; operating expenses down 8% YoY
- 40% of Lapiplasty surgeons using ≥1 new bunion system (up from 35% in Q1 2026)
- New product launches: SuperBite Compression Screw and HyperPlate XM systems
Financial Impact
Revenue beat of ~$1.5M (3.4%) and EPS beat of $0.06 (20%) vs consensus; guidance raise narrows the decline range
Risk Factors
- Revenue still declining YoY (-4%) and company remains unprofitable
- Litigation costs ($2.1M in Q2) and restructuring charges ($0.8M) weigh on margins
- Macroeconomic headwinds could dampen elective bunion surgery demand
- Competition from minimally invasive bunion solutions may pressure market share
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001630627-26-000017 |
| Document: tmci-20260807.htm | 0001630627-26-000017 |
| Document: 0001630627-26-000017-index-headers.html | 0001630627-26-000017 |
| Document: 0001630627-26-000017-index.html | 0001630627-26-000017 |
| Document: 0001630627-26-000017.txt | 0001630627-26-000017 |
| 8-K Data (Synthetic) | 0001630627-26-000017 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 7, 2026 8w ago | 8-K | $4.76 $4.81 | ▲ +1.05% | ▲ +1.45% | $4.39 (−7.77%) |
Jul 13, 2026 11w ago | Court Ruling | $4.58 $4.67 | ▼ −1.97% | ▲ +1.22% | $4.39 (+4.15%) |
May 8, 2026 21w ago | Press Release | $2.01 $3.51 | ▼ −74.63% | ▼ −74.60% | $4.39 (−118.41%) |
Apr 24, 2026 23w ago | Press Release | $1.98 $2.84 | ▲ +43.43% | ▲ +39.41% | $4.39 (+121.72%) |
Apr 9, 2026 25w ago | 8-K | $1.53 $1.93 | ▲ +26.14% | ▲ +18.58% | $4.39 (+186.93%) |
Apr 6, 2026 25w ago | DEFA14A | $1.44 $1.83 | ▲ +27.08% | ▲ +18.10% | $4.39 (+204.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access